HomeAbout UsPortfolioNewsContact Us

  • POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES

    Domain expertise, global resource, long-term capital

  • PORTFOLIO NEWS

    ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
    2023年3月28日
        Funding from new and existing investors will support pivotal Phase 3 and additional studies...
    China’s NMPA Clears Phase 3 IND Application for Alebund Pharmaceutical’s AP301, a New-generation Iron-based Phosphate Binder, to Treat Hyperphosphatemia in Dialysis Patients
    2023年3月17日
    March 17, 2023, Shanghai, China—Alebund Pharmaceuticals (“Alebund” or the “Company”) announced...
    Eluminex Biosciences Closes $40+ Million Series B Financing to Continue the Development of Innovative Ophthalmic Assets and Recombinant Human Collagen Technology
    2023年2月28日
      SUZHOU, China and SAN FRANCISCO, Feb. 27, 2023 /PRNewswire/ -- Eluminex Biosciences (Suzhou)...
    Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
    2023年2月3日
    SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. ...
    Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
    2022年12月22日
      RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States...
    Abbisko Therapeutics announces preliminary Phase I safety and efficacy results of Irpagratinib (ABSK011) in patients in second-line hepatocellular carcinoma with FGF19 overexpression
    2022年12月15日
    15 December 2022, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter)...
    Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion
    2022年11月8日
    -- Agreement includes aggregate upfront and target nomination fees of up to $21.5 million for up...
    Neukio Biotherapeutics completed Series A-1 financing, to accelerate discovery and development of next generation cell therapy products
    2022年9月2日
    SHANGHAI, Sept. 2, 2022 /PRNewswire/ -- Neukio Biotherapeutics, a company committed to developing...
    More Posts

Company

 

Shanghai

Room 2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.

 

 

Hong Kong

Room 606-7, St. George's Building, 2 Ice House Street, Central, Hong Kong

 

 

US

2735 Sand Hill Road, Suite 210

Menlo Park, CA 94025

copyright © 2018 Lilly Asia Ventures all rights reserved.

沪公网安备 31010102005458号
|
沪ICP备12003647号-1
    All Posts
    ×
    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More